Last reviewed 2026-05-28 · How we verify

Camphonium (TRIMETHIDINIUM METHOSULFATE)

Phase 2 active Small molecule ✓ Verified May 2026

Camphonium (generic name: TRIMETHIDINIUM METHOSULFATE) is a trimethidinium drug. It is currently in Phase 2 development.

Camphonium works by interacting with a specific target in the body, although its exact mechanism of action is currently unknown.

Camphonium is a small molecule with the synonyms METHOSULFATE DE TRIMETHIDINIUM, METOSULFATO DE TRIMETIDINIO, and TRIMETHIDINIUM METHOSULFATE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TRIMETHIDINIUM METHOSULFATE
Drug class	trimethidinium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Camphonium is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't yet know exactly how it does that or what it does to the cell. More research is needed to understand how Camphonium works and what it does in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Camphonium CI brief — competitive landscape report
Camphonium updates RSS · CI watch RSS

Frequently asked questions about Camphonium

What is Camphonium?

Camphonium (TRIMETHIDINIUM METHOSULFATE) is a trimethidinium drug.

How does Camphonium work?

Camphonium works by interacting with a specific target in the body, although its exact mechanism of action is currently unknown.

What is the generic name of Camphonium?

TRIMETHIDINIUM METHOSULFATE is the generic (nonproprietary) name of Camphonium.

What drug class is Camphonium in?

Camphonium belongs to the trimethidinium class. See all trimethidinium drugs at /class/trimethidinium.

What development phase is Camphonium in?

Camphonium is in Phase 2.

Drug class: All trimethidinium drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing